Table 1.

Patient characteristics

Age (years)	Present disease manifestations	DMARD	Pred. (mg/day)	Anti-dsDNA (U/ml)	SLAM score
Active SLE patients
391	Nephritis, arthritis	None	5	68	8
26	Skin, haematological	None	6·25	251	14
56	Arthritis	AZA	10	ND	13
34	Nephritis, arthritis	Chlorambucil	15	139	9
43	Nephritis, skin	None	5	> 400	26
52	Nephritis	None	10	314	8
64	Haematological	None	5	ND	12
19	Nephritis	AZA	20	ND	16
29	Nephritis, lymphadenopathy	None	15	> 400	25
231	Nephritis, APS	None	0	65	9
47	Skin, haematological, fever, nephritis		302	> 400	16
36	Arthritis, mental depression	AZA	ND	56	12
371	Nephritis	MMF	8·75	52	9
45	Nephritis	None	7·5	15	10
44	Haematological, hair loss, musculoskeletal	AZA, AM	5	Neg	15
39			8·1	104	12
Inactive SLE patients
38	Inactive	AZA, AM	2·5	Neg	1
59	Inactive	None	6	Neg	2
69	Inactive	AZA	4	Neg	4
39	Inactive	AM2	0	Neg	4
35	Inactive	None	0	110	6
80	Inactive	None	0	Neg	4
58	Inactive	None	0	ND	4
44	Inactive	None	0	Neg	1
391	Inactive	MMF	25	24	6
231	Inactive	None	20	28	6
371	Inactive	MMF	10	ND	5
47			6	Neg	4

Medians shown below columns in bold types.

AM, antimalarials; APS, antiphospholipid syndrome; AZA, azathioprine; DMARD, disease modifying anti-rheumatic drug; MMF, mycophenolate mofetil; ND, not determined; Pred., prednisolone; SLAM, systemic lupus erythematosus activity measurement; SLE, systemic lupus erythematosus.

¹Patients analysed during active and inactive SLE.

²Recent onset.